Masood Khan joins KCAS team

Becomes senior director of ligand binding assay services

KCAS, a US bioanalytical laboratory specialising in research and analytical services for pharmaceutical, biotech, animal health and medical device companies, has added Masood Khan to its growing team of experts. He will serve as senior director of ligand binding assay (LBA) services.

For nearly 20 years, Dr Khan has led wide-ranging research on strategic planning for LBA programmes, as well as the development of GLP-compliant and non-GLP assays for the conduct of ligand binding studies. He has chaired and organised many conferences and lectures at annual forums and meetings of the American Association of Pharmaceutical Scientists’ (AAPS) and has helped establish the LBAB-Focus Group, a specialist division of AAPS.

Dr Khan has worked in executive capacities for several contract research organisations (CROs) and pharmaceutical companies including MDS Life Sciences, Covance, NeuroBiotech, Medlmmune and most recently the National Institute of Health.

Dr Khan received his PhD in biochemistry from Aligarh University, India, and has conducted post-doctoral studies at the National Institute of Environmental Health Sciences in North Carolina and McGill University, Royal Victoria Hospital in Canada.

You may also like

Analysis

Conjugation chemistry key to unlocking next-generation oligonucleotide therapies, says Bachem

As demand for oligonucleotide therapeutics accelerates, Bachem's Director of Oligonucleotide Production explains how conjugation chemistry is helping CDMOs overcome delivery challenges
Manufacturing

UK pharmaceutical manufacturers struggling to meet F-Gas compliance amid ageing cooling infrastructure

A new Aggreko report reveals that nearly all UK pharmaceutical manufacturers are facing barriers to upgrading cooling systems ahead of the accelerating F-Gas phase-down timeline
Regulatory

UK REACH ATRm: CBA welcomes progress but warns of significant hurdles ahead

The Chemical Business Association has acknowledged long-awaited movement on the UK REACH Alternative Transitional Registration model following DEFRA's consultation response, but cautioned that cost burdens likely running into hundreds of millions of pounds
Manufacturing

Labtex - Fresh thinking and innovative solutions

Labtex states: "We are proud to provide unique solutions for laboratories and pilot plants across the UK"
Regulatory

Lonza Nominates Stephen Fry as Independent Board Member

Basel, Switzerland, 31 March 2026 – The Lonza Board of Directors today announced the nomination of Stephen Fry as an Independent Member of the Board. Subject to his election at the Lonza Group Annual General Meeting (AGM) in May 2026, Stephen will also be appointed a member of the People and Governance Committee and the Audit and Compliance Committeex
Research & Development

Applied Biopharm Consulting awarded Innovation funding to validate AI-powered AAV vector engineering platform

Irish biotech consultancy Applied Biopharm Consulting has secured an Innovation Voucher from the Local Enterprise Office Cork North & West to collaborate with an academic partner in validating its computational platform for adeno-associated virus vector optimisation through laboratory testing
Manufacturing

Nemera partners with Therakind to expand nasal drug delivery portfolio with DriDose dry powder platform

The manufacturer has announced a strategic partnership with UK pharmaceutical company Therakind to advance the DriDose intranasal dry powder platform, adding dry powder delivery capabilities to complement Nemera's existing liquid nasal formulation offering
Subscribe now